


## A. COMPLIANCE REPORT ON CORPORATE GOVERNANCE REPORT FOR THE QUARTER ENDED 31.12.2024

Name of the Entity: Akums Drugs and Pharmaceuticals Limited


I. Composition of Board of Directors												
Title (Mr./Ms)	Name of Director	PAN/DIN	Category (Chairperson/ Executive/ Non-Executive/ independent/ Nominee)	Initial Date of Appointment	Date of Re-appointment	Date of cessation	Tenure	Date of Birth	No of Directorship in listed entities including this listed entity [in reference to Regulation 17A]	No of Independent Directorship in listed entities including this listed entity [in reference to proviso to regulation 17A (1)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr.	Sanjeev Jain	AAAPJ1897J 00323433	Executive Director	19-04-2004	30-06-2023	-	-	11.04.1966	1	0	1	0
Mr.	Sandeep Jain	AAAPJ1891Q 00323476	Executive Director	19-04-2004	30-06-2023	-	-	05.08.1967	1	0	2	0
Mr.	Sanjay Sinha	AGHPS6644K 03627342	Executive Director	17-01-2024	17-01-2024	-	-	01.11.1958	1	0	0	0
Mr.	Sunil Kumar Thakur	ADEPT9727E 03266370	Non-Executive Director	17-01-2024	17-01-2024	-	-	03.02.1978	1	0	1	0
Mr.	Kewal Kundanlal Handa	AAAPH3516N 00056826	Non-Executive - Independent Director	16-03-2022	16-03-2022	-	33.16	22.08.1952	5	5	10	5
Ms.	Matangi Gowrishankar	AAGPG8973J 01518137	Non-Executive - Independent Director	16-03-2022	16-03-2022	-	33.16	27.02.1958	7	7	4	0
Mr.	Nand Lal Kalra	AFTPK6497D 05268554	Non-Executive - Independent Director	27-09-2015	13-02-2020	-	111.5	05.02.1950	1	1	2	0
Mr.	Satwinder Singh	ACAPS5953J 00164903	Non-Executive - Independent Director	17-01-2024	17-01-2024	-	11.15	06.07.1964	1	1	4	2



II. Composition of Committees					
Name of Committee	Whether Regular chairperson appointed	Name of Committee Members	Category (Chairperson/Executive/Non- Executive /independent/Nominee) \$	Date of Appointment	Date of Cessation
1. Audit Committee	Yes	Mr. Kewal Kundanlal Handa	Independent Director – Chairman	17-01-2024	
		Mr. Sandeep Jain	Executive Director – Member	17-01-2024	
		Mr. Nand Lal Kalra	Independent Director – Member	17-01-2024	
		Mr. Sunil Kumar Thakur	Non-Executive Director – Member	17-01-2024	
		Ms. Matangi Gowrishankar	Independent Director – Member	17-01-2024	
		Mr. Satwinder Singh	Independent Director – Member	17-01-2024	
2.Nomination & Remuneration Committee	Yes	Ms. Matangi Gowrishankar	Independent Director – Chairperson	17-01-2024	
		Mr. Nand Lal Kalra	Independent Director – Member	17-01-2024	
		Mr. Sunil Kumar Thakur	Non-Executive Director – Member	17-01-2024	
		Mr. Kewal Kundanlal Handa	Independent Director – Member	17-01-2024	
		Mr. Satwinder Singh	Independent Director – Member	17-01-2024	
3. Stakeholders' Relationship Committee	Yes	Mr. Satwinder Singh	Independent Director – Chairperson	17-01-2024	
		Mr. Sandeep Jain	Executive Director – Member	17-01-2024	
		Mr. Sanjeev Jain	Executive Director – Member	17-01-2024	
		Mr. Nand Lal Kalra	Independent Director – Member	17-01-2024	
4. Risk Management Committee	Yes	Mr. Sanjeev Jain	Executive Director – Chairperson	17-01-2024	
		Mr. Sandeep Jain	Executive Director – Member	17-01-2024	
		Mr. Kewal Kundanlal Handa	Independent Director – Member	17-01-2024	
		Mr. Nand Lal Kalra	Independent Director – Member	17-01-2024	
		Ms. Matangi Gowrishankar	Independent Director – Member	17-01-2024	
		Mr. Sumeet Sood	Chief Financial Officer – Member	17-01-2024	



<b>III. Meetings of Board of Directors</b>					
Date(s) of Meeting (if any) in the previous quarter (01 <sup>st</sup> Jul, 2024 to 30 <sup>th</sup> September, 2024)	Date(s) of Meeting (if any) in the relevant period (01 <sup>st</sup> Oct, 2024 to 31 <sup>st</sup> December, 2024)	Whether requirement of Quorum met	Number of Directors present	Number of independent Directors present	Maximum gap between any two consecutives (in number of days)
24-07-2024 01-08-2024 24-08-2024	09-11-2024	Yes	8	4	76
<i>*to be filled in only for the current quarter meetings</i>					
<b>IV. Meetings of Committees</b>					
Date(s) of meeting of the committee in the relevant period (01 <sup>st</sup> October, 2024 to 31 <sup>st</sup> December, 2024)	Whether requirement of Quorum met (details)	Number of Directors present*	Number of independent directors present	Date(s) of meeting of the committee in the previous quarter (01 <sup>st</sup> July, 2024 to 30 <sup>th</sup> September, 2024)	Maximum gap between any two consecutives (in number of days)
<b>Audit Committee</b>					
09-11-2024	Yes	6	4	24-08-2024	76
<b>Nomination &amp; Remuneration Committee</b>					
09-11-2024	Yes	5	4	24-08-2024	76
<b>Stakeholders' Relationship Committee</b>					
-	-	-	-	-	-
<b>Risk Management Committee</b>					
09-11-2024	Yes	5	3	-	-
<b>V. Related Party Transactions</b>					
<i>Subject</i>			<i>Compliance Status (Yes/No/NA)</i>		
Whether prior approval of audit committee obtained			Yes		
Whether shareholder approval obtained for material RPT			NA		
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee			Yes		
<p>Note:1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.</p> <p>2. If status is "No" details of non-compliance may be given here.</p>					



**VI. Affirmations:**

1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
2. The composition, role and terms of reference of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
  - a. Audit Committee
  - b. Nomination & remuneration Committee
  - c. Stakeholders' Relationship Committee
  - d. Risk Management Committee
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015 and the Companies Act, 2013.
5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of the board of directors may be mentioned here.

**For Akums Drugs and Pharmaceuticals Limited**

  
**Dharamvir Malik**

**Company Secretary and Compliance Officer**

**Membership No.: F8596**

**Date: 30-01-2025**

**Place: Delhi**



**B. INVESTOR GRIEVANCE REDRESSAL REPORT**

Investor Grievance Redressal Report	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of Quarter	0

**C. DISCLOSURE OF ACQUISITION OF SHARES OR VOTING RIGHTS IN UNLISTED COMPANIES**

The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-papa 1 of papa A of Part A of Schedule III are given below:

S. No.	Name of the unlisted company in which shares are voting rights have been acquired	Date of acquisitions	Aggregate holding (% shares or voting rights) as at the ned of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at end of the quarter
	No acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III	NA	NA	NA	NA

**D. DISCLOSURE OF IMPOSITION OF FINE OR PENALTY**

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:


S. No.	Name of the Authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication form the authority	Details of the violation(s) / contravention(s) committed or alleged to be committed	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
	No	NA	NA	NA	NA



### E. DISCLOSURE OF UPDATES TO ONGOING TAX LITIGATIONS OR DISPUTE

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

S. No.	Name of the opposing party	Date of initiation of litigation / dispute	Status of litigation / dispute as per last disclosure	Current Status of the litigation /dispute
1.	Assessing Officer (NFAC)	26/09/2021	For the assessment year 2017-18, the Deputy Commissioner of Income Tax, Chandigarh (“DCIT”) passed an order under section 144 of the Income Tax Act, 1961 (“Act”) dated September 26, 2021 (“Assessment Order”) whereby the income of Akums Lifesciences Ltd. (now merged with Pure & Cure Healthcare Pvt. Ltd.) was assessed to be ₹ 617.76 million. The DCIT also issued a notice of demand (“Demand Notice”) under section 156 of the Act for tax liabilities amounting to ₹ 734.46 million. Along with the Assessment Order and the Demand Notice, the DCIT issued a notice for initiation of penalty (“Penalty Notice”) under section 274 read with section 270A of the Act. ALL filed a civil writ petition dated November 15, 2021 (“Writ Petition”) before the High Court of Punjab and Haryana (“P&H HC”) for quashing and grant of stay against the Assessment Order, Demand Notice and the Penalty Notice. Vide order dated March 25, 2022, the P&H HC directed that the demand raised pursuant to the Assessment Order be not acted upon. The matter is currently pending.	Counter Reply filed by the department. Next date fixed for hearing is 02.04.2025.



Annexure -

Details of Cyber security incidence	
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	NO
Other details of cyber security incidence or breaches or loss of data event	NA
Number of cyber security incidence or breaches or loss of data event occurred during the quarter	NA

